



PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS

CINRYZE[®]
C1 esterase inhibitor (human)



Jeanie, a real HAE patient

TAKING CHARGE OF YOUR HEREDITARY ANGIOEDEMA (HAE) TREATMENT WITH SELF-ADMINISTRATION

Choosing to self-administer CINRYZE® (C1 esterase inhibitor [human]) can offer you more flexibility in your journey. Through Path to Independence™, infusion nurses are available for hands-on training and ongoing support throughout the infusion training process to ensure you are comfortable and confident in managing your own infusions.

Patients should only self-administer after being trained by a healthcare provider.

Once you learn how to self-administer from a healthcare provider, you can follow the instructions in this brochure. The Full Prescribing Information, enclosed in the pocket of this brochure, contains the complete list of step-by-step instructions as well.

Remember, sticking to your prescribed treatment schedule is necessary for CINRYZE to help prevent HAE attacks. Even if you experience fewer or no attacks, missing a dose can result in a breakthrough attack.

To help stay on track with your treatment, use a calendar, planner, or journal to keep records of your infusion schedule, appointments, and supply order reminders.

Indication

CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).

Important Safety Information

You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Please see additional Important Safety Information on page 11 and the Full Prescribing Information available at www.cinryze.com.

DOSING

- ▷ Dose of CINRYZE® (C1 esterase inhibitor [human]) for routine prophylaxis against HAE attacks is 1,000 Units every 3 or 4 days
- ▷ CINRYZE comes in 500 Unit vials, so 2 vials are needed to administer a single dose
- ▷ CINRYZE should be infused over 10 minutes (an infusion rate of 1 mL/min)

PREPARATION OF CINRYZE®

Wash your hands before you begin. Ensure you are working on a flat surface and your work area is thoroughly cleaned and germ-free throughout the process.

- ▷ **Prior to preparation, CINRYZE should be stored at 2°C to 25°C (36°F to 77°F) and be protected from light**
- ▷ Visually inspect CINRYZE after preparation. CINRYZE should be colorless to slightly blue and free from particles. Do not administer if murky or discolored
- ▷ Each CINRYZE vial is for single use only. CINRYZE does not contain a preservative. Any vial that has been entered should be used promptly. Partially used vials should be discarded in accordance with biohazard procedures
- ▷ Do not mix CINRYZE with other materials
- ▷ Do not use if frozen
- ▷ Do not use after expiration date

Supplies needed:



2 Vials of CINRYZE
(500 Units each)



2 Vials of Sterile Water for Injection, USP
(diluent, 5 mL each)



2 Mix2Vial® Transfer Devices



Alcohol Prep Pads
(wipes)



1 10-mL Silicone-Free Syringe
A silicone-free syringe is recommended for preparation and administration of CINRYZE

Do not reuse the Mix2Vial device.

CINRYZE should be administered within 3 hours of preparation.

Call your healthcare provider if you have any questions on the preparation or self-administration of CINRYZE. **Patients should only self-administer after being trained by a healthcare provider.**

CINRYZE®
C1 esterase inhibitor (human)

PREPARATION OF CINRYZE®


Note that 2 vials of CINRYZE® (C1 esterase inhibitor [human]) are required for each dose.

CINRYZE comes as a freeze-dried powder supplied in a vacuum-sealed vial, and must be reconstituted (mixed) with Sterile Water for Injection, USP before it can be administered.

- 1** Let the vials of CINRYZE and the vials of Sterile Water for Injection, USP (diluent) reach room temperature.
- 2** Remove the caps from the vials of CINRYZE and the Sterile Water for Injection, USP (diluent) to show the center part of the rubber stopper.
- 3** Wipe the top of each vial with an alcohol wipe or swab and allow it to dry. Do not blow on the stopper to dry it faster. After cleaning, do not touch the rubber stopper with your hand or allow it to touch any surface.
- 4** Remove the protective covering from the top of the Mix2Vial® device packages. Do not remove the device from the package.
- 5** **Sterile Water for Injection, USP (diluent) vial must be penetrated before the CINRYZE vial to prevent loss of vacuum.**

Place the Sterile Water for Injection, USP (diluent) vial on a flat surface and insert the blue end of the Mix2Vial device into the diluent vial, pushing down until the spike penetrates the rubber stopper and the device snaps in place.  The Mix2Vial device must be positioned completely upright before penetrating the rubber stopper.

Remove the plastic package from the Mix2Vial device and discard it. Take care not to touch the exposed end of the device.




Please see the Full Prescribing Information available at www.cinryze.com, including the FDA-Approved Patient Labeling and Instructions for Use.

6

Place the vial of CINRYZE® (C1 esterase inhibitor [human]) on a flat surface. Turn the Sterile Water for Injection, USP (diluent) vial upside down and insert the clear end of the Mix2Vial® device into the CINRYZE vial, pushing down until the spike penetrates the rubber stopper and the device snaps into place. □

The Mix2Vial device must be positioned completely upright before penetrating the rubber stopper. The Sterile Water for Injection, USP (diluent) will automatically flow into the vial of CINRYZE because the vacuum in the vial will draw the Sterile Water for Injection, USP (diluent) into the CINRYZE vial. **If this does not happen, do not use the product.**




7

Once all the Sterile Water for Injection, USP (diluent) is in the CINRYZE vial, gently swirl (do not shake) the CINRYZE vial until all the powder is dissolved. □ Disconnect the Sterile Water for Injection, USP (diluent) vial by turning it counterclockwise. □

Do not remove the clear end of the Mix2Vial device from the CINRYZE vial.

Look at the final solution before using it to make sure that CINRYZE is completely dissolved. The solution should be clear, colorless to slightly blue, and be without any evidence of cloudiness. Do not use if the solution is cloudy or otherwise discolored and call Shire Medical Information at 1-800-828-2088.

Prepare 2 vials of CINRYZE for 1 dose.
Repeat steps 5-7 using a new Mix2Vial device.



Call your healthcare provider if you have any questions on the preparation or self-administration of CINRYZE. **Patients should only self-administer after being trained by a healthcare provider.**

CINRYZE®
C1 esterase inhibitor (human)

PREPARATION OF CINRYZE®


8 Utilizing a sterile, disposable 10 mL syringe, draw back the plunger to allow approximately 5 mL of air into the syringe.

9 Attach the syringe onto the clear end of the Mix2Vial® device by turning it clockwise. □



10 Turn the CINRYZE vial upside down and inject air into the vial. □
Slowly pull as much dissolved CINRYZE as possible into the syringe. □

Continued on next page.




Please see the Full Prescribing Information available at www.cinryze.com, including the FDA-Approved Patient Labeling and Instructions for Use.

While holding the vial upside down, detach the syringe from the vial by turning it counterclockwise and releasing it from the Mix2Vial® device. □

Remove any air bubbles by gently tapping the syringe with your finger and slowly pushing the air out of the syringe.

Using the same syringe, repeat steps 8-10 with a second vial of CINRYZE® (C1 esterase inhibitor [human]) to make one complete 10 mL dose.



11

Dispose of the vials with the Mix2Vial devices attached to them. CINRYZE should be administered promptly after preparation in the syringe.

Call your healthcare provider if you have any questions on the preparation or self-administration of CINRYZE. **Patients should only self-administer after being trained by a healthcare provider.**

CINRYZE®
C1 esterase inhibitor (human)



SELF-ADMINISTRATION (INTRAVENOUS INJECTION) OF CINRYZE®

Your healthcare provider will teach you the proper technique to safely administer CINRYZE® (C1 esterase inhibitor [human]). It is important that CINRYZE is injected directly into a superficial vein and not injected into surrounding tissues or an artery.

CINRYZE should be administered at room temperature promptly after preparation in the syringe.

Supplies needed:



**Dissolved CINRYZE in
10 mL Silicone-Free Syringe**



**Infusion Set With
Winged Adapter
(butterfly needle with tubing)**



Tourniquet



**Alcohol Prep Pads
(wipes)**



Watch



Medical Tape



Bandages




Sharps Container

Please see the Full Prescribing Information available at www.cinryze.com, including the FDA-Approved Patient Labeling and Instructions for Use.

1

Remove plastic cap and attach the infusion set to the syringe containing the dissolved CINRYZE® solution. □

Fill the tubing with dissolved CINRYZE by gently pushing the plunger of the syringe, being careful not to spill. This process replaces the air in the tubing with dissolved CINRYZE. □



2

Apply a tourniquet and prepare the injection site by wiping the skin well with an alcohol wipe.

Important Safety Information

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

- ▷ wheezing
- ▷ difficulty breathing
- ▷ chest tightness
- ▷ turning blue (look at lips and gums)
- ▷ fast heartbeat
- ▷ swelling of the face
- ▷ faintness
- ▷ rash
- ▷ hives

Call your healthcare provider if you have any questions on the preparation or self-administration of CINRYZE. **Patients should only self-administer after being trained by a healthcare provider.**

CINRYZE®
C1 esterase inhibitor (human)




SELF-ADMINISTRATION (INTRAVENOUS INJECTION) OF CINRYZE®

- 3** As instructed by your healthcare provider, insert the butterfly needle of the infusion set tubing into your vein. Tape the needle to keep it in place. □

Remove the tourniquet.

Make sure that the needle is in a vein and inject the dissolved CINRYZE® (C1 esterase inhibitor [human]) slowly over 10 minutes (approximately 1 mL/min). □



- 4** After infusing CINRYZE, remove the infusion set and discard. Cover the infusion site with a bandage. The amount of drug product left in the infusion set will not affect your treatment.

Dispose of all unused solution and the empty vials. Used butterfly needle and syringe should be disposed of in an appropriate sharps container to ensure safe disposal and handling.

It is a good idea to record the lot number from the CINRYZE vial every time you use CINRYZE.

Call your healthcare provider if you have any questions on the preparation or self-administration of CINRYZE. **Patients should only self-administer after being trained by a healthcare provider.**

Indication

CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).

Important Safety Information

You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Tell your healthcare provider about all of your medical conditions, including if you:

- ▷ have an indwelling catheter/access device in one of your veins.
- ▷ have a history of blood clots, heart disease, or stroke.
- ▷ are taking birth control pills or androgens.
- ▷ are pregnant or planning to become pregnant. It is not known if CINRYZE can harm your unborn baby.
- ▷ are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby.

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

- ▷ wheezing
- ▷ difficulty breathing
- ▷ chest tightness
- ▷ turning blue (look at lips and gums)
- ▷ fast heartbeat
- ▷ swelling of the face
- ▷ faintness
- ▷ rash
- ▷ hives

Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

- ▷ pain and/or swelling of an arm or leg with warmth over the affected area
- ▷ discoloration of an arm or leg
- ▷ unexplained shortness of breath
- ▷ chest pain or discomfort that worsens on deep breathing
- ▷ unexplained rapid heart rate
- ▷ numbness or weakness on one side of the body

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You can also report side effects to Shire Medical Information at 1-866-888-0660.

Please see the Full Prescribing Information available at www.cinryze.com, including the FDA-Approved Patient Labeling and Instructions for Use.

CINRYZE®
C1 esterase inhibitor (human)



Path to Independence™ is a training and support program designed to help teach patients, family members, or caregivers how to self-administer or administer CINRYZE.

For more information, contact your OnePath®
Case Manager at 1-866-888-0660.

**Please see Important Safety Information on page 11.
Please see the accompanying Full Prescribing Information, including
the FDA-Approved Patient Labeling and Instructions for Use.**



CINRYZE, Path to Independence, OnePath, and the associated logos are either registered trademarks or trademarks of Shire or its affiliates.

Mix2Vial is a registered trademark of Medimop Medical Projects, Ltd. in the United States and other jurisdictions.

© 2016 Shire. All rights reserved. S11351 02/2016

